logo-loader
viewOrgenesis

Orgenesis strikes collaboration, license deal for exosome technologies with ExcellaBio

Orgenesis CEO Vered Caplan says exosomes have shown ‘significant promise’ as a novel alternative to whole cell therapies with ‘potentially superior safety’

A magnified image of an exosome
The Germantown, Maryland, biopharmaceutical company has expertise in developing advanced cell therapies and manufacturing

Orgenesis Inc (NASDAQ:ORGS), a developer of advanced cell therapies, announced Thursday that it has inked a collaboration and licensing deal with ExcellaBio Ltd for exosome-related technologies developed by Dr Sabina Glozman.

Exosomes, also called extracellular vesicles (EVs), were first discovered nearly 30 years ago. Secreted by various cells into body fluids, exomes contain cell-specific payloads of proteins, lipids, genetic material and signaling molecules. These small membrane vesicles do much more than clean up a cell’s trash — they also carry signals to distant parts of the body, where they can impact multiple dimensions of cellular life. Exosomes are currently widely used in disease diagnosis and treatment.

Orgenesis will now enjoy access to technologies developed by Glozman, including an exosome-like membrane nanostructure (Bioxome) and related processes for the production of exosomes. According to the agreement, Orgenesis will enjoy exclusive, worldwide rights to certain commercial applications of the technology arising from the collaboration.

Shares in Orgenesis climbed 0.4% to $4.90 in morning trade.

READ: Orgenesis leads the charge at an exciting time for cell therapy

“We are excited to collaborate with ExcellaBio and its founder Dr Glozman, on this breakthrough platform for the scalable production of exosomes/EVs,” Orgenesis CEO Vered Caplan said in a statement. “Exosomes have shown significant promise as a novel alternative to whole cell therapies with potentially superior safety, efficacy and storage/manufacturing properties.”

Based in Germantown, Maryland, Orgenesis is a biopharmaceutical company with expertise in developing advanced cell therapies and manufacturing.

On the manufacturing side, the company’s subsidiary MaSTherCell Global helps companies shorten lead times and lower costs in getting cell therapies and products to the market.

On the technology side, the company’s subsidiary Orgenesis is a pioneer in transdifferentiation, which simply means cell reprograming.

“I am honored to partner with Orgenesis, a leader and pioneer in the field of cell therapy,” said Glozman, who is a director at ExcellaBio Ltd. “By combining our unique exosome/EV technology with Orgenesis’ expertise within the cell therapy arena, this collaboration has the potential to enhance many lives. We believe our Bioxome technology has broad potential across a number of indications ranging from liver fibrosis to aesthetic indications, CNS disorders, as well as many other serious medical conditions.”

Contact Uttara Choudhury at [email protected]

Follow her on Twitter@UttaraProactive 

Quick facts: Orgenesis

Price: 7.26 USD

NASDAQ:ORGS
Market: NASDAQ
Market Cap: $159.69 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Orgenesis named herein, including the promotion by the Company of Orgenesis in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Orgenesis signs deal with Accellix, invites Academy Award...

Orgenesis (NASDAQ: ORGS) President and CEO Vered Caplan joined Steve Darling from our Proactive New York studio to discuss the company signing an important co-development deal with Accellix. That company specializes in assay migration and delivery platforms for on-demand process...

on 11/04/2019

2 min read